Supreme Court blocks $6 billion Purdue Pharma deal

Must read

Gilead Sciences on track to snap its six-day winning streak

Shares of Gilead Sciences (NASDAQ:GILD) were on track to end their six-day gaining streak on Thursday, noting their first decline since November 29....

AbbVie shares set for seventh straight session of gains

AbbVie (NYSE:ABBV) shares were on track for their seventh consecutive session of gains on Thursday, as the stock rose nearly 1% to 147.54...

Meta Platforms on track to snap six-day red streak

Meta Platforms' (NASDAQ:META) shares are on track to break a 6-day losing streak after losing about 4.4% over the last 6 trading sessions....

Kenvue gains amid hearing on purported Tylenol linkage to autism in children (update)

Scott Olson/Getty Images News Update 1:35pm: Updates shares, adds court hearing ended. Kenvue Inc. (NYSE:KVUE), the consumer health company...

By Devan Cole and Ariana de Vogue | CNN

The Supreme Court on Thursday blocked Purdue Pharma from going forward with bankruptcy proceedings, which the Biden administration has called an “unprecedented” arrangement that would ultimately offer the Sackler family broad protection from opioid-related civil claims.

In agreeing to pause the settlement, the court also said it would take up the case and hear arguments this December.

The case arose after the reorganization in bankruptcy of OxyContin manufacturer Purdue Pharma – stemming from litigation arising from claims over its role in fueling the opioid addiction crisis.

Until recently, Purdue was controlled by the Sackler family, who withdrew billions of dollars from the company before it filed for bankruptcy. The family has now agreed to contribute up to $6 billion to Purdue’s reorganization fund on the condition that the Sacklers receive a release from civil liability.

The government, representing the US Trustee, has called the plan “exceptional and unprecedented” in court papers, noting that lower courts have divided on when parties can be released from liability for actions that caused societal harm.

More articles

Latest article

Gilead Sciences on track to snap its six-day winning streak

Shares of Gilead Sciences (NASDAQ:GILD) were on track to end their six-day gaining streak on Thursday, noting their first decline since November 29....

AbbVie shares set for seventh straight session of gains

AbbVie (NYSE:ABBV) shares were on track for their seventh consecutive session of gains on Thursday, as the stock rose nearly 1% to 147.54...

Meta Platforms on track to snap six-day red streak

Meta Platforms' (NASDAQ:META) shares are on track to break a 6-day losing streak after losing about 4.4% over the last 6 trading sessions....

Kenvue gains amid hearing on purported Tylenol linkage to autism in children (update)

Scott Olson/Getty Images News Update 1:35pm: Updates shares, adds court hearing ended. Kenvue Inc. (NYSE:KVUE), the consumer health company...

FedEx shares on track to record its seventh straight session of gains

Sundry Photography/iStock Editorial via Getty Images Global delivery firm FedEx (NYSE:FDX) shares are on track to record its seventh...